Format

Send to

Choose Destination
F1000Res. 2017 Aug 24;6:1556. doi: 10.12688/f1000research.11952.1. eCollection 2017.

Update on umbilical cord blood transplantation.

Author information

1
Stem Cell Transplant Program, University of Virginia Health System, Charlottesville, VA, USA.

Abstract

Allogeneic hematopoietic cell transplant is a curative procedure for many patients with leukemia, lymphoma, myelodysplasia, myeloproliferative neoplasms, and genetic disorders. Umbilical cord blood transplantation is a graft source for patients who do not have a matched donor in their family or in the unrelated registry. It is particularly difficult for Black, Hispanic, and White patients of non-Western European background to find fully matched adult volunteer donors. An estimated 700,000 umbilical cord blood units have been donated for public use, and over 40,000 umbilical cord blood transplantations have been performed. Over 25,000 patients have been cured with this approach.

KEYWORDS:

Allogeneic hematopoietic cell transplantation; Regenerative Medicine; Umbilical cord blood transplantation

Conflict of interest statement

Competing interests: The author declares that she has no competing interests.No competing interests were disclosed.No competing interests were disclosed.

Publication type

Publication type

Supplemental Content

Full text links

Icon for F1000 Research Ltd Icon for PubMed Central
Loading ...
Support Center